SLOTS-CAPITAL
Slots Capital, et af de mest populære online casinoer i verden, er nu tilgængelig for flere spillere end nogensinde før, når de for første gang lander i flere nye lande.
Det betyder, at spillere i Belgien, Rumænien, Grækenland, Danmark, Finland, Irland, Letland og Luxembourg nu kan nyde godt af den førsteklasses online casinooplevelse, som Slots Capital tilbyder.
Hvis du elsker spillemaskiner, så er Slots Capital stedet, hvor du kan vælge mellem mere end 300 spil fra kendte udviklere såsom Rival, Saucify, Dragon og Qora.
Faktisk har vi for nylig styrket vores spillemaskiner og bordspil-lobby med titler fra eftertragtede spilstudier, herunder Rival Gaming, Dragon Gaming, Saucify Gaming og Qora Gaming.
Vi vil også tilføje spillemaskiner fra Arrow's Edge i de kommende uger, men i mellemtiden kan spillere prøve de nyeste titler ved at udforske vores lobby, som inkluderer:
- Dead Beats
- Irish Wishes
- Lucky Macau
- Panda Playtime
- Sands of Space
- Twin Dragons
- Viking Victory
- Win Another Day
- Wrath of Medusa
- Yeti Hunt i3D
Slots Capital er ikke kun kendt for at være den bedste destination for spillemaskiner, vores spillere elsker også de daglige bonusser, bonusser uden indbetaling, superhurtige udbetalinger og 24/7 kundesupport.
Vi er mobilvenlige, hvilket betyder, at du kan tilgå alle vores spillemaskiner samt vores generøse bonusser, betalingsmuligheder og kundesupport fra din smartphone eller tablet.
Hos Slots Capital vil vi gerne byde nye spillere velkommen med en enorm generøs indbetalingsmatchbonus; når du indbetaler 150 kr., tilføjer vi 450 kr. til din saldo, hvilket giver dig 600 kr. at spille med totalt.
Hvis ikke det var nok, tilbyder vi også match-bonusser på dine næste tre indbetalinger, hvor du kan modtage 250 %, 300 % og 400 %!
Sharon Kane, Slots Capital , udtalte: "Vi er så begejstrede over at have lanceret Slots Capital på otte nye markeder, og for at spillere kan nyde en af de bedste online casinooplevelser på markedet.
Vi har for nylig føjet en række efterspurgte udbydere til vores allerede imponerende lobby, hvilket viser vores engagement til at tilbyde spillere det bredest-mulige udvalg af spillemaskiner at vælge imellem.
Hvis du ikke allerede har spillet hos Slots Capital, hvad venter du så på - udnyt vores gavmilde velkomsttilbud og kom og se, hvad alle taler om."
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210611005178/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum